CollPlant Biotechnologies (CLGN) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CollPlant Biotechnologies is the larger company by market cap ($7.5 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLGN | TRAW |
|---|---|---|
| Share price | $3.97 | $0.4803 |
| Market cap | $7.51M | $7.38M |
| 1-day change | +14.74% | +0.27% |
| EPS (TTM) | $-9.33 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.80 | $3.27 |
| 52-week low | $2.64 | $0.43 |
| Distance from 52-week high | -85.19% | -85.31% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +108.20% |
| Average volume | 352.86K | 569.02K |
| Shares outstanding | 1.89M | 15.37M |
| Employees | 39 | 4 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Health Care · Industrial Specialties · 39 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CLGN vs TRAW FAQ
Which is bigger, CollPlant Biotechnologies or Traws Pharma?
CollPlant Biotechnologies (CLGN) is larger, with a market capitalization of $7.51M compared with $7.38M for Traws Pharma (TRAW).
Are CollPlant Biotechnologies and Traws Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for CollPlant Biotechnologies and Biotechnology: Pharmaceutical Preparations for Traws Pharma.